Sato, Y., Iguchi, M., Kato, Y., Morioka, H., Hirabayashi, A., Tetsuka, N., . . . Yagi, T. (2020). Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days. Nagoya J Med Sci.

Sato, Yoshitaka, et al. "Number of Concomitant Drugs With Thrombocytopenic Adverse Effects and the Extent Inflammatory Response Resolution Are Risk Factors for Thrombocytopenia in Patients Treated With Linezolid for More Than 14 Days." Nagoya J Med Sci 2020.

Sato, Yoshitaka, et al. "Number of Concomitant Drugs With Thrombocytopenic Adverse Effects and the Extent Inflammatory Response Resolution Are Risk Factors for Thrombocytopenia in Patients Treated With Linezolid for More Than 14 Days." Nagoya J Med Sci 2020.